Identity
a synthetic, once-weekly, peptide GLP-1/glucagon dual-receptor agonist with a deliberately balanced 1:1 activity ratio, from Altimmune (a small clinical-stage biotech). Unlike weight-first incretins, it's designed liver-first — its lead indication is MASH (metabolic dysfunction-associated steatohepatitis, the serious form of fatty-liver disease) — with obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) also in development.
Mechanism (as proposed)
pemvidutide co-activates two receptors in a balanced 1:1 ratio. The GLP-1 receptor drives the familiar incretin effects — appetite suppression, satiety, weight loss. The glucagon receptor adds what GLP-1-only drugs lack: direct hepatic actions that increase energy expenditure/fat oxidation and reduce liver fat, inflammation, and fibrosis — the basis of the MASH strategy — while also helping preserve lean mass (a metabolic consequence of the glucagon arm). The deliberate 1:1 balance distinguishes it from GLP-1-dominant duals; the trade-off with glucagon agonism is careful attention to glucose and heart-rate effects, managed by the balanced design and dosing. In short: GLP-1 for weight/appetite, glucagon for liver and muscle-sparing — a mechanism tuned for MASH-plus-obesity rather than weight alone.